MSB ...., page-8

Have just done some research on the company and it seems it is of the upmost quality.

1. Commercial deals with biotech giants with Teva, Lonza and Celgene.
2. Management seems to have a proven track record, including former chief executive officer of Roche, William Burns.
3. CEO has skin in the game with 50 million + shares.
4. Strong cash position and balance sheet.

It seems the company could be entering a sweet spot as many clinical trials are reaching phase 3/FDA approval.

Seems the share price has been belted over the last 2 years, any reason for this? Or just people expecting higher revenues/more products to be commercialised in a quicker fashion?

Any more relevant feedback about the company would be appreciated.